Cite this article
Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites
1 Department of Gynaecology and Obstetrics, Chaoyang Hospital, Capital Medical University, Beijing, China
2 Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China
Eur. J. Gynaecol. Oncol. 2018, 39(4), 615–620; https://doi.org/10.12892/ejgo4178.2018
Published: 10 August 2018
Objective: To observe the clinical efficacy of lentinan combined with cisplatin and paclitaxel in the treatment of ovarian cancer with ascites. Materials and Methods: Two hundred and twelve cases of patients with epithelial ovarian cancer (EOC) and ascites were retrospectively analyzed. Patients were divided into TP (taxinol + platinol) group and TP + lentinan group according to the chemotherapy regimen. Results: The effective rate (CR + PR) in TP group (98 cases) was 31.6% and disease control rate (CR +PR + SD) was 80.6%. The effective rate in TP + lentinan group (114 cases) was 50.9% and the disease control rate was 88.6%, with statistical difference compared with TP group. The control of ascites in TP + lentinan group was better than TP group. The common adverse reactions of chemotherapy in TP + lentinan group was relative mild with reduced incidence. Conclusion: Lentinan combined with chemotherapy could enhance the efficacy of chemotherapy and control of the ascites.
Epithelial ovarian cancer